Our Private Equity Group provides trusted counsel derived from deep industry knowledge to established as well as up-and-coming private equity firms. We represent firms of every size across the spectrum of investment strategies, and we build long-standing relationships with our clients. As active participants in the private equity industry, we are able to advise our clients on the latest innovations, as well as current market practices and trends.
SOFIE Biosciences to Receive Strategic Growth Investment From Trilantic North America
- Client News
- January 28, 2024
Paul, Weiss is advising SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization, in a substantial strategic growth investment made by global private equity firm Trilantic North America. Trilantic’s investment will be made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business. Financial terms of the transaction were not disclosed. The transaction is expected to close later in 2024, subject to customary closing conditions and regulatory approvals.
The Paul, Weiss team is led by corporate partner Jeffrey Marell, tax partner Scott Sontag and corporate counsel Ji Lu, and includes corporate counsel Jason Tyler; executive compensation partner Jarrett Hoffman and counsel Sasha Belinkie; litigation partners Jaren Janghorbani and Aidan Synnott; intellectual property partner Claudine Meredith-Goujon; and environmental counsel William O'Brien.